Immunomedics is a biopharmaceutical company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer.
Business Model:
Revenue: $21.5M
Employees: 201-500
Immunomedics was acquired by
Gilead Sciences.
The acquisition happend on 2020-09-13.
Details of the transaction were not public
Address: 300 The American Road
City: Morris Plains
State: NJ
Zip: 07950
Country: US
Immunomedics is a biopharmaceutical company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer.
Contact Phone:
+19736058200
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
4/19/1984
Ticker Symbol:
IMMU
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2017 | Post-IPO Equity | 1 | - |
New Enterprise Associates New Enterprise Associates |
5/2014 | Post-IPO Equity | $30M | 5/2017 | Private Placement | $125M | 1/2017 | Post-IPO Equity | 1 | - |
New Enterprise Associates New Enterprise Associates |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|